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Materials and Methods 
Small molecule exposure.   Larval zebrafish were raised on a 14 hour/10 hour light/dark 
cycle at 28.5oC.  At four days post fertilization (dpf), a single larva was pipetted into 
each of 80 wells of a 96-well plate (7701-1651; Whatman, Clifton, NJ) containing 650 µL 
of standard embryo water (0.3 g/L Instant Ocean, 1 mg/L methylene blue, pH 7.0).  
Larvae were then exposed to small molecules beginning at ~96 hours post fertilization 
(hpf) by directly pipetting a 10 mM stock solution (in DMSO) into each well (10 animals 
per compound) for a final chemical concentration of ~10-30 μM and no more than 0.3% 
DMSO. This concentration of DMSO has no effect on behavior.  Small molecules were 
obtained from the following libraries and screened at the following final concentrations:  
1) Spectrum library from Microsource Discovery at ~30 µM (Gaylordsville, CT); 2) 
Prestwick library from Prestwick Chemical at ~15 µM (Illkirch, France); 3) 
neurotransmitter (cat#2810), ion channel (cat#2805), and orphan ligand libraries 
(cat#2825) from Biomol International at ~15 µM (now Enzo Life Sciences, International; 
Plymouth Meeting, PA); 4) Sigma LOPAC library at ~10 μM (Sigma-Aldrich, St. Louis, 
MO).  Behavioral recording began at 11 PM, approximately 110 hpf.    
 
Locomotor activity analysis.  The behavioral assay is adapted from (S1).  Locomotor 
activity was monitored for 60 hours using an automated video tracking system 
(Videotrack; Viewpoint Life Sciences, Montreal, Quebec, Canada) with a Dinion one-
third inch Monochrome camera (model LTC0385; Bosch, Fairpoint, NY) fitted with a 
fixed-angle megapixel lens (M5018-MP; Computar) and infrared filter.  The movement 
of each larva was recorded using the Videotrack quantization mode, and data from two 
cameras were collected in alternating minutes by one computer.  The 96-well plate and 
camera were housed inside a custom-modified Zebrabox (Viewpoint, LifeSciences) that 
was continuously illuminated with infrared lights and illuminated with white lights from 9 
AM to 11 PM.  The 96-well plate was housed in a chamber filled with circulating water to 
maintain a constant temperature of 28.5oC.  The Videotrack threshold parameters for 
detection used were: detection threshold, 40; burst, 25; freeze, 4; bin size, 60 seconds.         
 
Data analysis.  The data was processed using custom PERL, Visual Basic Macros for 
Microsoft (Seattle, WA) Excel, and Matlab (version R2007a; The Mathworks, Inc).  Any 
one minute bin with less than 0.1 second of total movement was defined as one minute 
of rest; a rest bout was defined as a continuous string of rest minutes (S1).  Rest 
latency was defined as the length of time from lights on or off to the start of the first rest 
bout.  Total activity was defined as the average amount of detected activity in seconds, 
including all rest bouts.  Waking activity was defined as the total amount of detected 
activity, excluding all one minute periods of rest.  These parameters were calculated for 
each experimental day and night, standardized to camera-matched DMSO controls, and 
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expressed as +/- standard deviations from controls for hierarchical clustering (see 
below).  We calculated the inter-assay variability as a coefficient of variation (standard 
deviation of all DMSO controls/mean of DMSO controls*100) for each measurement.  
For non-normal distributions, including rest length, rest latency, and wakingactivity, the 
coefficient of variation was calculated following a Box-Cox transformation to a normal 
distribution.  The coefficient of variations (expressed as a %) are as follows: total rest, 
day 1, 42.3%, day 2, 42.1%, night 1, 24.4%, night 2, 19.9%; rest bouts, day 1, 27.3%, 
day 2, 21.9%, night 1, 16.7%, night 2, 11.3%; rest bout length, day 1, 14.6%, day 2, 
12.9%, night 1, 15.6%, night 2, 11.3%; rest latency, day 1, 35.7%, day 2, 45.8%, night 
1, 13.2%, night 2, 20.0%; total activity, day 1, 35.5%, day 2, 28.1%, night 1, 36.3%, 
night 2, 29.9%; waking activity, day 1, 15.5%, day 2, 17.9%, night 1, 18.9%, night 2, 
15.6%.  Much of the variability is due normal inter-individual variation.            
 
To generate time series data for average rest per 10 minutes and average waking 
activity per 10 minutes (red traces, e.g. Figure 2B-F), these two parameters were 
averaged across all 10 replicate animals in 10 minute intervals and then normalized to 
camera matched controls by dividing each 10 minute rest and 10 minute waking activity 
measure by the mean daytime rest and activity for camera matched controls, 
respectively.  For comparison, 10 representative sets of DMSO controls (10 larvae each 
set; e.g. blue traces in Figure 2B-F) are plotted in each time series.  The same DMSO 
controls are shown in all graphs for clarity.   
 
To identify compounds that significantly altered behavior, each parameter was 
compared to camera-matched DMSO controls by Student‟s t-test.  Compounds were 
chosen for further analysis if either: 1) the compound altered the same parameter in the 
same direction at a p value < 10-5 for two consecutive days or nights, 2) the compound 
affected a behavioral parameter at p<10-10 within the first 24 experimental hours, or 3) 
the compound altered rest latency at p<0.001 for two consecutive days or nights but 
had little effect on other parameters. These parameters were chosen to select the 
largest manageable set of small molecules with the strongest and most consistent 
effects on behavior while minimizing false positives and compounds with spurious short-
term behavioral alterations.  Biological targets were assigned to compounds based on 
annotations in the Pharmaprojects, Drugbank, Drugs@FDA, and Leadscope Marketed 
Drugs databases, as well as information supplied by the library vendors and detailed 
manual literature searches for each compound.   
 
Hierarchical and k-means clustering analysis.  Clustering analysis was performed with 
Cluster 3.0 (adapted by Michiel de Hoon from Cluster, written by Michael Eisen, (S2)) 
and visualized using TreeView (written by Michael Eisen, (S2)).  Hierarchical clustering 
was performed using Pearson uncentered correlation and average linkage.  The 
parameters were weighted as follows:  total rest, 1.0; rest bouts, 0.8; rest bout length 
0.3, rest latency, 1.0; total activity and waking activity, 1.0.  K-means clustering was 
performed using k=24 and Euclidean distance.  To determine the relative position of the 
k-clusters, the average vector for each cluster was calculated, and these 24 vectors 




Correlation Analysis:  All correlation analysis was performed in Matlab (version R2007a; 
The Mathworks, Inc).  The weighted, uncentered Pearson‟s correlation coefficients were 
calculated for all compound pairs. Compounds were assigned to pharmacological 
classes as described above.  Compounds were considered to share targets if both their 
target assignment and activity (i.e. agonist or antagonist) overlapped for at least one 
target.   
 
Rank Correlation Analysis:  To perform rank correlation analysis for adrenergic 
antagonists and ERG blocking drugs, the average weighted uncentered Pearson‟s 
correlation coefficient between each compound of the identified cluster and every other 
small molecule was calculated.  Each small molecule was then assigned a rank based 
on their mean correlation, with rank 1 being the highest mean correlation.  Compounds 
that showed ERG or adrenergic antagonist activity were identified by their 
pharmacological assignments, and the Kolmogorov-Smirnov statistic was used to 
assign the p value for whether ERG or adrenergic antagonist compounds were enriched 
among the higher ranking compounds.  The rank correlations were graphically 
represented in Treeview (S2).        
 
Dose Correlation Analysis.  Compounds were ordered from Sigma-Aldrich (St. Louis, 
MO), dissolved in DMSO to a stock concentration of 30 or 45 mM and tested in the 
locomotor activity assay at final concentrations of 0.15, 0.45, 1.5, 4.5, 15, and 45 µM, or 
0.1, 0.3, 1.0, 10, and 30 µM (0.3% DMSO final concentration).  Each concentration was 
tested on 10-20 larvae.  To generate the fingerprint for each concentration, the 
behavioral parameter measurements were standardized to camera-matched DMSO 
controls and expressed as +/- standard deviations from controls.  Two-tailed t-test 
assessments (Bonferroni corrected for multiple comparisons) determined statistically 
significant differences of each measurement relative to camera-matched controls.  The 
correlation matrices were generated by calculating the weighted, uncentered Pearson‟s 
correlation coefficient between the fingerprints for all concentration pairs.  The 
fingerprint, significance, and correlation matrix heat maps were generated using Matlab 
(version R2007a; The Mathworks, Inc.).              
 




Supplemental Texts 1-7 
 
Supplemental Text 1.  Psychotropic Drug Discovery   
The limitations of in vitro drug screening are particularly acute for the development of 
drugs that modulate the central nervous system (CNS).  Surveys of drug discovery 
success show that CNS drugs take longer to develop (12.6 years versus 6.3 years for 
cardiovascular drugs) and fail to reach the market more often (7% success rate versus 
15%) than other therapeutic indications (S4).  The CNS poses a particular challenge to 
drug discovery because the brain cannot be modeled in vitro.  Indeed, most modern 
psychotropic drugs were first developed for non-psychotropic uses and serendipitously 
discovered to have behavior-altering side effects (e.g. the MAO inhibitor, iproniazid, was 
developed to treat tuberculosis and found to alter mood, and the tricyclic antidepressant 
imipramine was first used as an anti-histamine, (S5)).  Furthermore, CNS drugs tend to 
produce undesirable side effects, including dizziness, tremors, lethargy, and seizures, 
which are difficult to predict at early stages of the drug discovery pipeline.  Also, the 
mechanism of action for many CNS drugs, including bipolar medications, 
antidepressants, and antipsychotics, is poorly understood and in many cases may 
depend on a compound‟s complex poly-pharmacological actions across multiple 
neurotransmitter systems (S6-7).  Indeed, efforts to increase efficacy and reduce side 
effects through the development of newer generations of drugs with more selective 
target profiles has to date achieved only limited success (S8-9). 
   
Alternatives or complements to in vitro target-based screens include phenotype-based, 
whole organism screens.  Such screens have several advantages.  First, whole-
organism screens need not be limited to single, well-validated targets.  In fact, whole 
organism screens can identify efficacious compounds with complex mechanisms of 
action.  Second, unwanted side effects, an obstacle in any drug discovery pipeline, can 
be detected at earlier stages, even during the primary screening process.  Third, 
compounds that produce a behavioral effect are bio-available, another major stumbling 
block to in vitro based drug discovery pipelines.  In principle, whole organism 
phenotypic screening could replace serendipity, but the requirement for large numbers 
of phenotyped animals is usually cost and time prohibitive.  Behavioral screening in 
zebrafish larvae offers a cost-effective model system for psychotropic drug 
characterization and discovery. 
 
Supplemental Text 2.  Dose 
Choosing the compound concentration is a challenge for any large-scale small molecule 
screen.  Effective doses can vary among compounds, but it is impractical in most cases 
to screen at multiple concentrations.  The decision to perform our screen in the 10-30 
µM range was based on the following considerations.  First, we were guided by several 
previous studies.  Developmental screens in zebrafish used concentrations of 10-50 µM 
(S10-12), single compound behavioral studies in zebrafish were done at 1-100 µM 
(S13-19), and the connectivity map cell-based screen was performed at 10 µM (S20, 
21).  Second, we performed a pilot screen of 96 compounds and found that only 10% of 
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the compounds were overtly toxic at the 30 μM range, a percentage deemed acceptable 
for screening.  Third, dose response curves on selected compounds indicated that a 
concentration of 10-30 µM was an effective range with consistent behavioral effects for 
most compounds (Table S1 and Fig. S4).  Specifically, we found that fingerprints for the 
same compound were strongly correlated (25/29 cases) across the statistically effective 
concentration range (Fig. S4).  These results show that the behavioral fingerprints are 
broadly stable across multiple doses.   
 
Supplemental Text 3.  Therapeutic Classes of Drugs Induce Correlated Behaviors 
To test the potential of the clustering analysis, we determined whether compounds that 
share targets are more likely to produce similar phenotypes (Fig. S5A-B).  Expanding 
this correlation analysis to 50 categories of drugs, we found, with few exceptions, that 
the correlations among related classes of compounds were much larger than chance 
(Fig. S5C).  In many cases, every intra-class pair-wise correlation was larger than the 
zero target correlation (see Figure Legend S5 for definitions of category abbreviations; + 
indicates agonist, - indicates antagonist), including the ADR-A2+ (median correlation = 
0.853; range = 0.352-0.974), SNRI (median = 0.775; range = 0.453-0.956), 5HT-1A+ 
(median = 0.791; range = 0.463-0.958), NEURO- (median = 0.759; range = 0.587-
0.894), DOPA-D1+ (median = 0.885; range =  0.766-0.927), and CHA-NA+ (median = 
0.833; range = 0.519-0.985) classes (Fig S5C).  In other examples, intra-class pair-wise 
correlations were much larger except for a few outliers, including the SSRI (median = 
0.767 ; range = 0.262-0.963), 5HT-1A- (median = 0.769; range = -0.02-0.930 ), 5HT-2- 
(median = 0.698; range = 0.187-0.977), DOPA-D2+ (median = 0.727; range = 0.072-
0.982), GABA- (median = 0.722; range = -0.05-0.972), HIST-H1-(ERG) (median = 
0.722; range = 0.229-0.911), and NMDA- (median = 0.651; range = -0.419-0.971) 
classes (Fig. S5C).  Not all classes had higher correlations than the no target class, 
including the adrenergic reuptake class (ADR-U; median = 0.257; range = -0.50-0.959) 
and the sodium channel antagonist class (CHA-NA-; median = -0.031; range = -0.513 – 
0.913).  This may reflect the heterogeneity of secondary targets for the compounds of 
these classes. 
 
Supplemental Text 4. Polypharmacology.  
Many compounds have multiple, potentially non-overlapping targets.  In such cases, 
one would expect that not all compounds that share targets produce similar phenotypes 
(Fig. S5A-C).  For example, outliers of the correlation analysis might reflect the difficulty 
in assigning compounds to single classes when in fact they have multiple targets.  This 
observation can be used to identify potential polypharmacological effects (Figs. S5C 
and S7).  For example, NMDA antagonist (NMDA-) outliers included compounds that 
also bind to σ-opioid receptors (e.g. 3-methoxymorphinan), the GABA antagonist 
(GABA-) outlier tert-butyl-bicyclophosphorothionate (TBPS) also potently blocks chloride 
channels, the serotonin receptor 1A antagonist (5HT-1A-) outlier S(-)UH-301 is also a 
dopamine D2/3 receptor agonist, and the dopamine D2 receptor agonist (DOPA-D2+) 
outlier pergolide is also a serotonin receptor agonist (Fig S5C).  Our correlation analysis 
can also uncover higher order associations among drugs with multiple targets, such as 
the high correlation between drugs that share dopamine reuptake inhibition and 
acetylcholine antagonism (Figure S7A-B).  Furthermore, the clustering analysis can 
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reveal unexpected associations between annotated drug classes.  For example, a 
cluster of known α1-adrenergic receptor antagonists (ifenprodil, terazosin, and 5-methyl-
urapidil) also cluster with several serotonin receptor modulators, including NAN-190, 
RU-24969, WAY-100635, spirotraxine, and buspirone (Fig. S7C-D).  Intriguingly, 
buspirone and spirotraxine do not strongly bind to α1-adrenergic receptors in vitro yet 
can show in vivo adrenergic activity in specific pharmacological contexts (22).  These 
results show that behavioral profiling can uncover associations between multi-target 
drugs whose properties are not fully predicted by in vitro studies.       
 
Supplemental Text 5. Pharmacological Conservation (Figs. S8-15).  
We systematically compared the behavioral effects of agonists and antagonists of the 
major neurotransmitter systems between zebrafish and mammals.  In most cases, 
confidence in the conservation between zebrafish and mammals is enhanced when 
multiple compounds known to affect the same target elicit similar phenotypes and when 
agonist/antagonist pairs elicit opposing phenotypes.  We discuss each class in more 
detail below. 
 
Adrenaline (Fig. S8).  In zebrafish, α2-adrenergic agonists decreased wakefulness with 
little effect on rest, while activation of β-adrenergic receptors selectively reduced total 
rest at night.  Conversely, β-adrenergic receptor antagonists increased total rest.  α1-
adrenergic antagonists gave a “mixed” phenotype of increased waking activity but also 
increased rest.  These effects are broadly consistent with those observed in mammals 
(S23-35).           
 
Serotonin (Fig. S9). The analysis of serotonin-regulating drugs is complicated because 
most, if not all, serotonin-modulating drugs have considerable affinity for non-serotonin 
receptors, especially dopaminergic and adrenergic receptors.  Thus, the drugs chosen 
for the table in Figure S9 combine serotonin-signaling selectivity, consistency of 
phenotype, and reproducibility (i.e. multiple hits within the screen of the same or similar 
compounds).  As often as possible, the drugs shown have known mammalian 
phenotypes (S36-55).  The complexity of the phenotypes we observed with serotonergic 
agonists and antagonists is similar to the controversial and contradictory nature of the 
mammalian literature pertaining to these drugs.  This may reflect the difficulty in 
isolating the drugs‟ effects on serotonin signaling from other secondary effects, 
differences between short-term and long-term exposure, or complex signaling 
interactions among different populations of serotonergic neurons in the brain.  For 
example, in mammals agonists and antagonists of serotonin receptor 1A both cause 
short-term reduction of sleep and increase in wakefulness followed by longer-term 
increases in sleep and reduced activity (S36-40, S45-47).  In long-term experiments, 
both classes of drugs increased rest in zebrafish.  Only buspirone had an observed 
short-term increase in waking during the first night of the experiment (black arrow in Fig. 
S9).  Serotonin receptor 2/3 antagonists have paradoxical effects in mammals, 
increasing both exploratory behavior and sleep (S38, S44, S49-52).  Similarly, both 
waking activity and total rest were increased in zebrafish.  Finally, SSRIs consistently 
decreased waking activity and increased rest in zebrafish; in human patients, SSRIs 
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often improve insomnia in depressed patients but can have biphasic effects on sleep, 
with long-term decreases in sleep in some mammalian models (S53-55).   
 
Dopamine (Fig. S10).  With one notable exception, dopamine receptor agonists and 
antagonists produce similar phenotypes in mammals and zebrafish (S56-67).  For 
example, the D2-receptor agonists consistently reduced waking activity and increased 
rest in zebrafish, as they do at low concentrations in mammals (S60-63).  This effect 
was receptor subtype selective, as the D2/D3 receptor agonists quinelorane and 
quinpirole only reduced waking activity (S64, S65).  As another example of 
conservation, D2-receptor antagonists, several of which are used as anti-psychotics, 
increase waking activity and rest in zebrafish and mammals (S57, S62, S67).  Previous 
work indicated that antipsychotics produce locomotor defects in zebrafish larvae (S15-
16).  The only clear examples of non-conserved pharmacology in our study were the 
dopamine D1 agonists (Fig. S10, marked in gray), all of which had little effect on waking 
activity but greatly increased total rest in zebrafish.  In all mammalian species tested, 
dopamine D1 agonists increased waking (S56-59).  This could indicate a distinct role for 
the zebrafish orthologs of D1 receptors in the control of behavior or that these dopamine 
D1 agonist drugs have altered target selectivity in zebrafish.                   
 
GABA (Fig. S11).  While many of the GABA-regulating benzodiazepine drugs were toxic 
at the concentrations used in our screen, the GABA-A agonists GBLD-345 and 
avermectin B1 increased total rest and had only a small effect on waking activity (S68).  
Although only represented by a single hit in the screen, the GABA-B agonist CGP-
13501 (Fig. S11, marked in gray) slightly increased waking activity at night with very 
modest increases in rest during the day, even though this drug is hypnotic in mammals 
(S69).  In contrast, many GABA-A antagonists dramatically increased waking activity, 
possibly reflecting pro-convulsant effects of these drugs on zebrafish larvae, which is 
consistent with the mammalian literature (S70-72) and with previous work in zebrafish 
(S13, S17, S19).  Tracazolate, an anxiolytic acting as an allosteric modulator of GABA-
A receptors, modestly increased waking activity in zebrafish; in mammals, tracazolate 
can both increase or decrease locomotor activity (S73, S74).  Intriguingly, the 
neuroactive steroid GABA agonists allopregnanolone, pregnanolone, and alfadolone 
increased both total rest and waking activity specifically at night (S75-77).  As 
neuroactive steroids have additional functions in mammalian brains, including 
modulation of NMDA receptors (S75), this mixed phenotype may reflect the 
polypharmacology of these compounds.    
 
Melatonin (Fig. S12).  Although only a few examples were present in our screen, 
melatonin-modulating drugs gave results that are consistent with those observed in 
mammals (S78-82) and previous work in zebrafish (S14).  Melatonin slightly increased 
rest in our long-term experiments.  In addition, the melatonin agonist 8-methoxy-1-
propionamidotetralin decreased waking activity and increased rest.  An exception was 
the agonist IIK7 (S78), which slightly increased waking activity at night and had small 




Histamine (Fig. S13).  Histamine antagonists identified in our screen tended to increase 
rest, decrease waking activity, or both.  This increased rest in zebrafish is consistent 
with the mammalian literature, although it should be noted that anti-histamine drugs that 
do not cross the blood-brain barrier in humans, such as loratadine, tend to be less 
sedating than the older generation of drugs that do cross the blood-brain barrier (S83-
87).  Our work is also consistent with previous work on anti-histamines in zebrafish 
larvae (S13, S18).  Notably, the anti-histamine diphenylpyraline increased waking 
activity, consistent with reports of psychostimulatory effects in rodents (S87).  Also, as 
noted in the main text and Figures 4C-D and S18, anti-histamines that block the human 
ether-a-go-go related potassium channel (ERG) consistently increased waking activity 
at night, with modest effects on rest in zebrafish larvae. 
 
Adenosine (Fig. S14).  Consistent with mammals, adenosine receptor agonists 
increased rest in zebrafish larvae, while adenosine receptor A1 antagonists increased 
waking activity and reduced rest (S88-93).  Although behavioral effects of the adenosine 
A3 antagonist MRS-1220 are unknown in mammals, it decreased waking activity and 
increased rest in zebrafish.  This phenotype is consistent with its inhibitory effects on 
MAO (Figure 3D).      
 
Glutamate (Fig. S15).  All NMDA receptor antagonists identified in the screen 
dramatically increased waking activity during the day and night, consistent with the 
effects observed in mammals (S94, S95).  Muscarinic glutamate receptor 5 (mGluR5) 
antagonists selectively increased rest, with little effect on waking activity.  Antagonists of 
mGluR5 can block drug-induced hyperlocomotion, down-regulate bursting of prefrontal 
cortical neurons in awake rats, and have anxiolytic properties in rodents (S96, S97).   
 
Supplemental Text 6.  Non-overlapping Regulation of Rest/Wake States.   
Many pharmacological agents selectively altered waking activity, rest latency, or total 
rest.  For example, verapamil related L-type calcium channel inhibitors increased rest 
with no effect on waking activity (Fig. S16), while β-adrenergic agonists, including 
clenbuterol and fenoterol, decreased rest only (Fig. S8).  Non-competitive NMDA 
receptor antagonists, including the psychotomimetics dizocilpine (MK-801) and L-
701324, predominantly increased waking activity with minimal effects on total rest (Figs. 
2C and S15), the D2/D3 agonist, ropinirole, predominantly decreased waking activity 
only (Fig. S10), and podocarpatrien-3-one analogs predominantly altered only rest 
latency (Fig. 4A).  These single parameter effects can also be selective for day versus 
night.  For example, many anti-inflammatory compounds only increased waking activity 
during the day (Figs. 2B, 4B and S17), while ERG-blocking drugs increased waking 
activity at night (Figs. 2E, 4C-D, S18).  Finally, some compounds can affect waking 
activity and total rest in opposite directions (e.g. increase both waking activity and total 
rest).  For example, the α1-adrenergic antagonists ifenprodil, the antimalarial 
quinacrine, and the steroidal GABA agonist alfadolone, increased both waking activity 
and total rest (Figs S7C, S11).  These observations suggest that the behavioral 
parameters of waking activity, total rest, and rest latency during the day and the night 




Supplemental Text 7.  High Throughput Behavioral Screening in Practice 
Behavioral profiling in zebrafish is highly efficient.  Our current zebrafish behavior room 
(~200 sq. ft.) has 16 cameras that can each observe 80 wells of a 96-well plate, for a 
total of 1280 larvae.  Using our original screening method of 10 larvae per compound 
and including 10 control wells for each camera, we can screen 112 compounds (16 
cameras x 7 drugs per camera) every three days, or 224 compounds per week.  Using 
the latest videotracking software, which can track all 96 wells of the plate, and cutting 
the number of larvae per drug to eight expands our capacity to 352 compounds per 
week (16 cameras X 11 drugs per camera X 2 runs per week).  A single technician can 
set up the entire behavioral room in less than 4 hours, including fish husbandry, larval 
pipetting, drug dispensing, and software setup (an 8 hour commitment per week).  
Expanding the screen to 115 cameras and 5 technicians (a total commitment of 40 
hours per week) would increase the throughput to more than 10,000 compounds per 




                          
       
Supplemental Figure and Table Legends 
 
Figure S1.  Expanded hierarchical clustering analysis.  This is an expanded version of 
Figure 2A in which the name of each chemical in the clustergram can be seen.  Each 
row represents a different chemical, and each column represents a behavioral 
measurement.  From left to right, these measurements are: the rest total, the number of 
rest bouts, the rest bout length, the rest latency, the total activity, and the waking 
activity.  The black bars indicate night measurements; the white bars indicate day 
measurements.  Yellow indicates that the value is increased relative to controls; blue 
indicates that the value is decreased, as in Figure 2A.  The measurements are 
normalized as standard deviations from control values. 
 
Figure S2.  Hierarchical and k-means clustering yield similar cluster architectures. Each 
row represents a different chemical, and each column represents a behavioral 
measurement.  From left to right, these measurements are: the rest total, the number of 
rest bouts, the rest bout length, the rest latency, the total activity, and the waking 
activity.  The black bars indicate night measurements; the white bars indicate day 
measurements.  Yellow indicates that the value is increased relative to controls; blue 
indicates that the value is decreased, as in Figure 2A.  The measurements are 
normalized as standard deviations from control values. 
 
Figure S3.  Expanded k-means clustergram. This is an expanded version of Figure S2 
in which the name of each chemical in the clustergram can be seen.  Each row 
represents a different chemical, and each column represents a behavioral 
measurement.  From left to right, these measurements are: the rest total, the number of 
rest bouts, the rest bout length, the rest latency, the total activity, and the waking 
activity.  The black bars indicate night measurements; the white bars indicate day 
measurements.  Yellow indicates that the value is increased relative to controls; blue 
indicates that the value is decreased, as in Figure 2A.  The measurements are 
normalized as standard deviations from control values. 
 
Figure S4.  Behavioral fingerprints are stable across a range of doses.  Select 
compounds were tested for behavioral effects at multiple concentrations (see Table S1 
for additional examples and summary data).  First, the fingerprints for each dose were 
calculated as standard deviations from DMSO controls („Fingerprint‟, left panels).  In 
general, these fingerprints are stable across multiple concentrations until the dose is too 
low to elicit a phenotype.  To assess the stability of single drug fingerprints over multiple 
concentrations, the Pearson uncentered correlation coefficient was calculated pairwise 
between each dose („correlation matrix‟, right panels).  With the exception of pergolide 
and several other ergoline derivatives, which have distinct fingerprints at high versus 
low concentrations, these examples have relatively stable fingerprints from the highest 
dose tested (45 μM) to the lowest effective doses (150 nM for NAN-190 and 
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betamethasone, 450 nM for ropinirole, 1.5 µM for clonidine and buspirone), as indicated 
by the high correlations (red boxes).  See Materials and Methods for additional 
information.                   
 
Figure S5.  Compounds that share biological targets have highly correlated behavioral 
fingerprints.  (A) The distribution of all pair-wise correlation coefficients (Pearson 
weighted, uncentered; see Materials and Methods) for compounds that share at least 1 
target (blue) is shifted to higher values compared to compounds that share 0 targets 
(magenta).  This skewing is strong despite the fact that these compounds can have 
many divergent targets in addition to the shared target.  Each pair of compounds is 
represented once, even if they share multiple targets.  (B)  Box-whisker plot comparing 
correlations between compounds with 0 shared targets, compounds with at least 1 
shared target, and repeats of the same compound from different chemical libraries. For 
each measure, the blue box represents the interquartile range between the 25th and 75th 
percentiles; the red line marks the sample median; the whiskers extend from the box 
ends to values within 1.5 times the interquartile distance; red crosses mark outlier 
values beyond the 1.5 interquartile distance from the box ends. (C)   Box-whisker plots 
of correlation coefficients within biologically related classes of compounds.  For 
comparison, the mean correlation of compounds that share 0 targets is plotted as a 
green line (correlation = 0.266). The number of compounds used for comparisons within 
each class is indicated (N).  See supplemental text 3 for a detailed discussion of specific 
classes.  For all classes, a (-) sign indicates an inhibitor/antagonist and a (+) sign 
indicates an agonist.  The classes are: α-adrenergic-receptor 1, ADR-A1; α-adrenergic 
receptor-2, ADR-A2; β-adrenergic, ADR-B; noradrenaline reuptake inhibitor, ADR-U-; 
serotonin/noradrenaline reuptake inhibitor, SNRI; selective serotonin reuptake inhibitor, 
SSRI; serotonin receptor-1A, 5HT-1A; serotonin receptor-1D, 5HT-1D; serotonin 
receptor-2, 5HT-2; serotonin receptor-2/3, 5HT-2/3; serotonin receptor 4, 5HT-4; 
monoamine oxidase inhibitor, MAO-; neurotransmitter inhibitor (reserpine class), 
NEURO-; dopamine receptor, DOPA; dopamine D1 receptor, DOPA-D1; dopamine D2 
receptor, DOPA-D2; dopamine D2/3 receptor, DOPA-D2/3; dopamine D3 receptor, 
DOPA-D3; dopamine D4 receptor, DOPA-D4; γ-butyric acid receptor, GABA; histamine 
H1 receptor, HIST-H1; ether-a-go-go-related potassium channel, ERG; adenosine 
signaling, ADS; metabotropic glutamate receptor 5, mGLUR5;  N-methyl-D-aspartic acid 
receptor, NMDA; acetylcholinesterase inhibitor, ACH-ES- IRev, irreversible; Rev, 
reversible; muscarinic acetylcholine receptor; ACH-M; nicotinic acetylcholine receptor, 
ACH-N; acetylcholine synthesis, ACH-SY; L-type calcium channel; CHA-CA-L; sodium 
channel, CHA-NA; peroxisome proliferator-activated receptor, alpha, PPAR-A.  
 
Figure S6.  Examples of compounds that share biological targets and/or structural 
similarity that give similar behavioral profiles.  (A)  Structurally divergent selective 
serotonin reuptake inhibitors (SSRIs) similarly decrease waking activity and increase 
rest.  (B) Structurally related insecticides dramatically increase waking activity 
independent of the time of day. The graphs represent the normalized waking activity 
and total rest for behavior-altering compounds (red trace; average of 10 larvae) and 




Figure S7.  Cluster analysis of multi-target compounds.   A dopamine reuptake inhibitor 
(DOPA-U) with muscarinic acetylcholine antagonist (ACH-M-) activity does not correlate 
well with (A) compounds with only DOPA-U activity or (B) compounds with only ACH-M- 
activity.  It does, however, show high correlation with other compounds known to share 
both properties (B).  (C) α1-adrenergic receptor antagonists (marked in blue) form a 
large cluster with serotonin modulators (marked in green) that are known to also have 
α1- adrenergic receptor antagonist activity in vivo. (D) Rank-correlations of compounds 
across the entire dataset compared to the α1-adrenergic receptor antagonist cluster of 
ifenprodil, terazosin, and 5-methyl-urapidil enriches for compounds with α1-adrenergic 
receptor antagonism.  In the rank-graph, the black lines indicate compounds with known 
α1-adrenergic antagonism; red indicates high correlation, green indicates low 
correlation.  Compounds with α1-adrenergic antagonism are highly enriched in the top 
ranks (p < 10-23; see Materials and Methods).  
 
Figure S8-15.  Comparison of the effects of  neuroactive drugs on rest/wake states in 
zebrafish to the effects in mammals.  The graphs represent the waking activity and rest 
for representative agonists and antagonists of each class (red trace; average of 10 
larvae) and DMSO controls (10 blue traces; average of 10 larvae each).  Each plotted 
example is typical for the entire class of compounds.  The tables provide a more 
comprehensive list of agonists and antagonists of each receptor subtype.  The tables 
summarize the overall direction and magnitude of the observed effects of the drugs on 
zebrafish wake and rest behavior (up arrow, increased; down arrow, decreased; a 
dashed line indicates no change; a small arrow indicates a smaller relative effect, while 
a large arrow indicates a larger relative effect).  See supplemental text 5 for a more 
detailed discussion of each phenotype. 
 
Figure S16.  The L-type calcium channel inhibitor, YS-035, dose dependently increases 
rest with minimal effects on waking activity.  (A) Waking activity and rest graphs are 
shown for three structurally related L-type calcium channel inhibitors (red trace = 
average of 10 larvae) and representative DMSO controls (10 blue traces = average of 
10 larvae).  (B) YS-035 increases the time spent at rest during both the day (red) and 
night (blue) in a dose dependent fashion.  Each point indicates the average minutes of 
rest per hour for 10 larvae at each YS-035 concentration.  The error bars represent +/- 
SEM.  (C) YS-035 has little or no effect on waking activity at all concentrations tested, 
suggesting that muscle function is not dramatically perturbed.  Each point indicates the 
average seconds of waking activity every 10 minutes during the day (red) or night (blue) 
for 10 larvae at each YS-035 concentration.  Error bars represent +/- SEM (B, C).          
 
Figure S17.  Examples of immunomodulators that co-cluster as daytime-waking activity 
enhancers. (A) The table lists anti-inflammatory agents that selectively increased 
daytime waking activity (expanded examples from Figure 4B). (B) Waking activity and 
rest graphs are shown for compounds from each major class (red trace = average of 10 
larvae) and representative controls (10 blue traces = average of 10 larvae).   
 
Figure S18.  ERG inhibitors, but not non-ERG blocking anti-histamine analogs, dose 
dependently increase waking activity at night. (A) Waking activity and rest graphs are 
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shown for two ERG-blocking compounds (red trace = average of 10 larvae) and 
representative controls (10 blue traces = average of 10 larvae).  Both compounds 
increased waking activity at night without affecting rest.  Psora-4, which blocks Kv1.3 
shaker channels, increased nighttime waking activity and also strongly decreased rest, 
a phenotype distinct from ERG blockers.  Thus, the ERG phenotype is not the result of 
general potassium channel misregulation.  (B) Dose response curves for ERG blocking 
and ERG non-blocking analogs are shown.  Each point indicates the waking activity at 
night (seconds per minute) averaged for 10 larvae.  Cisapride and dofetilide, which have 
ERG blocking activity, dose-dependently increased nighttime wakefulness, while the 
non-ERG blocking histamine H1 receptor antagonists fexofenadine and cetirizine had 
no effect on wakefulness.  Another non-ERG blocking anti-histamine, loratadine, 
reduced waking activity.  Error bars represent +/- SEM.  The 0 M concentration is a 
DMSO control.     
 
Table S1. Summary of dose response experiments for selected compounds indicates 
fingerprints are stable across several concentrations.  This table is an expansion of the 
dose response fingerprints shown in Fig. S4.  Note that only ergoline-derived 
compounds (bottom of table) have complex dose dependent effects (i.e. different 
nontoxic fingerprints at high versus low concentrations).  This complex dose 
dependence is likely due to the high affinity that many ergoline drugs have for multiple 
receptor families and sub-types, including dopamine, serotonin, and adrenergic 
receptors (for example, see (S98)). 
Figure S1















































































Betamethasone ARACH- LIPCOR+ IM- GluR+
Clenbuterol Hydrochloride ADR-B-2+
Telmisartan ANG-2-1- PPAR-G+




Chlorophyllide Cu Complex Sodium Salt
Oxiconazole Nitrate FUNG-
Sulfaguanidine BACT-
Benzyl Penicillin Potassium BACT-
Retinoic Acid p-Hydroxyanilide APOP+
Pimozide DOPA-D-2- 5HT-2-A- ADR-A-1- DOPA-U-
Chlorpromazine Hydrochloride DOPA-D-2- DOPA-D-1- 5HT1-2- HIST-H-1-
Mitotane ESTR- CHA-NA?
SB 228357 5HT-2-B/C-
Maprotiline Hydrochloride ADR-U- 5HT-U-(weak)
Amitryptiline Hydrochloride ADR-U- 5HT-U- CHA-K-
R(-)-Isoproterenol (+)-Bitartrate ADR-B-2+ ADR-B-1+
Maprotiline Hydrochloride ADR-U- 5HT-U-(weak)
Carbenoxolone Sodium
I-OMe-Tyrphostin AG 538 KI-IGF-1-
(-)-Eseroline Fumarate OPI-M+ ACH-(weak)
Bacitracin BACT-
Leflunomide DH-HYO- KI-GFPL- ALOX5-
Meclizine Hydrochloride HIST- ACH-
Pancuronium Bromide ACH-N-
Fenoldopam DOPA-D-1-A+ ADR-A-2+
Chloroethylclonidine Dihydrochloide ADR-A-1- ADR-A-2+
Mecamylamine Hydrochloride ACH-N-
1-Benzyl-1-Methyl-4-Cyclopentylmethoxycarbonylpiperidinium Bromide ACH-T-




























Valproate Sodium HDAC- GABA+
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Betamethasone ARACH- LIPCOR+ IM- GluR+
Mefloquine Hydrochloride CALM-
Clobetasol Propionate ARACH- LIPCOR+ IM- GluR+
Flumethasone ARACH- LIPCOR+ IM- GluR+
Desoxycorticosterone Acetate COR-M+ MR+
Ethylene Glycol-Bis(2-Aminoethylether)-N,N,N,N-Tetraacetic Acid ACE-2- CHEL+
Dexamethasone ARACH- LIPCOR+ IM- GluR+
Propentofylline ES-P-C- ADS-/+
Bopindolol  Malonate ADR-B-1-
Betamethasone Valerate ARACH- LIPCOR+ IM- GluR+
Bretylium Tosylate ADR-B- NA/K-ATPase-
Pancuronium Bromide ACH-N-
Cepharanthine APOP- NF-KB- IM-
Ursolic Acid ARACH- LIPCOR+ IM- GluR+
Benzamil Hydrochloride CHA-NA-Ca-
Cefoxitin Sodium Salt SY-CW- BACT-
Papaverine Hydrochloride ES-P-C-4-
Medrysone ARACH- LIPCOR+ IM- GluR+
6-alpha-Methylprednisolone ARACH- LIPCOR+ IM- GluR+
6,7-Dichloroquinoxaline-2,3-dione EAA-G- NMDA-
L-689560 EAA-G- NMDA-
7-Chlorokynurenic Acid EAA-G- NMDA-
SDZ 220-581 EAA-G- NMDA-
IEM-1460 EAA-G- AMPA-R- NMDA-
Finasteride RED-5A-
Bufexamac SY-PG- COX- OX-C-
Ro 20-1724 ES-P-C-4-
Cisapride 5HT-4+ ACH+(indirect) CHA-K-
(+)-Tubocurarine Chloide ACH-N- ACH+ 5HT-3-




Sinapic Acid Methyl Ether
Dizocilpine Maleate EAA-G- NMDA-











3-(1H-Imidazol-4-yl)Propyl Di(p-Fluorophenyl)Methyl Ether Hydrochloride HIST-H3-/+
Dichlorodiphenyltrichloroethane CHA-NA+ INSECT-
Tracazolate Hydrochloride GABA-A- GABA-A+
1,4-PBIT Dihydrobromide NO-S-
Menadione VITA+
















NAME Activity 1 Activity 2 Activity3 Activity 4
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Loxapine Succinate DOPA-D-1- DOPA-D-2- 5HT-2- (indirect?)
Propazine HERB-
Bepridil Hydrochloride CHA-CA- CHA-NA- CHA-K-
1S,9R-Hydrastine GABA-A-
Dacthal HERB-
Chlordane GABA-A- INSECT- ATPP-Ca/Mg-ATPP-Na/K-




Naftopidil Dihydrochloride ADR-A-1- ADR-U-? 5HT-2-?
Clozapine 5HT-2- DOPA-D-2- ADR- HIST-H-1-
Halofantrine Hydrochloride CHA-K-
Amperozide Hydrochloride 5HT-2- DOPA-D-2-






Dihydroergotamine Mesylate 5HT-1-D+ 5HT-1-A+ ADR-A-2-ADOPA-D-2/D-3
Methiothepin Maleate 5HT-1-2- DOPA-D-2-
Mianserin ADR-U- ADR-A-2- HIST- 5HT-2-A/2-C-
Methoxychlor CHA-NA+ INSECT-
Toxaphene CHA-NA+ INSECT-
Heptachlor GABA-A- INSECT- ATPP-Ca/Mg-ATPP-Na/K-
Aldrin GABA-A- INSECT- ATPP-Ca/Mg-ATPP-Na/K-
Bromo-3-Hydroxy-4-(Succin-2-yl)-Caryolane gamma-Lactone
Cyproterone Acetate ANDR-
Promethazine Hydrochloride HIST-1- ACH-M- 5HT-2- calmodulin-





Deptropine Citrate HIST- ACH-M-
Clemastine HIST-1- ACH-M-?
Spermine Tetrahydrochloride EAA-G- EAA-G+ NMDA-
Homopterocarpin
Aconitine CHA-NA+
Cinnarazine CHA-CA- HIST-H-1- DOPA-D-2-ACH-M-
Verapamil Hydrochloride CHA-CA-










Meclozine Dihydrochloride HIST- ACH-
CGP-13501 GABA-B+
Mesulergine Hydrochloride DOPA-D-2+ 5HT-2-C-
Thioridazine Hydrochloride DOPA-D-2- 5HT-2- ADR- CHA-K-










Ro 25-6981 hydrochloride EAA-G- NMDA-NR2-B-
Droperidol DOPA-D-2- CHA-K-
Ethynodiol Diacetate PROG+ ESTR+
Bromocryptine Mesylate DOPA-D-2+ CREB+ SSTATIN




Cephaeline Dihydrochloride Heptahydrate 5HT-4+?
LY-53857 5HT-2-
Amodiaquine Dihydrochloride






Saquinavir Mesylate PROT- TNF-alpha+ PROL-
Butylparaben ESTR?
Ketanserin Tartrate 5HT-2- DOPA?
Papaverine Hydrochloride ES-P-C-4-
Nomegestrol Acetate PROG+ ANDR-
PD 168077 DOPA-D-4+
Quinacrine Hydrochloride ACH-M+ Lipase-A-2- OX-LP-5-
Ifenprodil Tartrate ADR-A-1- EAA-G- NMDA- CHA-K(GIRK)-
Phenamil CHA-NA-




Strophanthidinic Acid Lactone Acetate ATPP-Na/K-
Domperidone DOPA-D-2-
Spiperone DOPA-D-2- 5HT-1-A- 5HT-2-A-
Spiperone Hydrochloride DOPA-D-2- 5HT-1-A- 5HT-2-A-
Pancuronium Bromide ACH-N-
Amsacrine Hydrochloride TO-2-
Dihydroergotamine Methanesulfonate 5HT-1-D+ 5HT-1-A+ ADR-A-2-ADOPA-D-2/D-3
Medroxyprogesterone Acetate DEC-OR- ANDR- ESTR+ PR+
WB 4101 Hydrochloride ADR-A-1-
3-Methoxymorphinan Hydrochloride EAA-G- NMDA- OPI-S+ DOPA-U-?
L-741626 DOPA-D-2-
AMI-193 5HT-2- DOPA-D-2-
Spiroxatrine 5HT-1-A- DOPA-D-2- ADR-A-2-
AMI-193 5HT-2- DOPA-D-2-
trans-Dehydroandrosterone ESTR+ ANDR+ GABA-A-
DO 897/99 DOPA-D-2/D-3-DOPA-D-3+ 5-HA-1-A ADR-A-1
Triptophenolide
Azaperone DOPA- HIST- ACH-
WB 4101 Hydrochloride ADR-A-1-
R(+)-Terguride 5HT-2-B- DOPA+/partial





Dihydroergocristine DOPA-D-2+ ADR-A+/- 5HT-2-
4-Androstene-3,17-dione ESTR- ANDR+
Pirenperone 5HT-2- DOPA-D-2-?
Ketanserin Tartrate 5HT-2- DOPA?
LY-165163 5HT-1-A+ DOPA-D-2-
Astemizole HIST-1- CHA-K-
Chlormadinone Acetate ANDR- ESTR+ PR+
Totarol BACT-
Metergoline Phenylmethyl Ester 5HT-1-D- 5HT-2- DOPA+
Acetopromazine Maleate Salt DOPA-








Figure S1(Cont) NAME Activity 1 Activity 2 Activity3 Activity 4
Prednicarbate ARACH- LIPCOR+ IM- GluR+
CNS-1102 EAA-G- NMDA-
Yohimbine Hydrochloride ADR-A-2-
Opipramol Dihydrochloride 5HT-2- OPI-S+ HIST-H-1- DOPA-D-2-
DCEBIO CHA-K+







Tranylcypromine Hydrochloride MAO- DOPA-D-2? 5HT-2-A?
L-750667 DOPA-D-4-
Dl-p-Chlorophenylalanine Methyl Ester Hydrochloride 5HT-SY-
(+/-)-Vesamicol Hydrochloride ACH-SY-
Loratadine HIST-1- CHA-K(A5)-
1-(3-Chlorophenyl)Piperazine Dihydrochloride 5HT-1-2+ 5HT-3-
Gedunol
1,3-Diethyl-8-Phenylxanthine ADS-A-1- ES-P-C-IV- Nf-kB
Zardaverine ES-P-C-3-
Dioxybenzone UV-









Spermine EAA-G- EAA-G+ NMDA-
Tert-Butyl-Bicyclo[2.2.2]Phosphorothionate GABA-A-
Indomethacin Morpholinylamide SY-PG- COX-1-2-




Apomorphine Hydrochloride DOPA+ COMT- TH-
6-(5H)-Phenanthridinone PARP-
Lysergol





CGS-12066A Maleate 5HT-1-B+ 5HT-1-D+
Dihydrocapsaicin VAN+















Haloperidol DOPA-D-1-2- NMDA- CHA-K-
Triflupromazine Hydrochloride DOPA-D-1/D-1-5HT-2-B- ACH-M-
Metergoline 5HT-1-D- 5HT-2- DOPA+
Imipramine Hydrochloride 5HT-U- ADR-U- ADS-A-1-
RX 821002 Hydrochloride ADR-A-2-
CV-3988 PAF-
Totarol-19-Carboxylic Acid
Clozapine 5HT-2- DOPA-D-2- ADR- HIST-H-1-
Amitriptyline Hydrochloride 5HT-U- ADR-U-
Norcyclobenzaprine 5HT-2-A-
Estradiol PROG+ ESTR+ SXR+
Chrysin DIUR+




WAY-100635 Maleate 5HT-1-A- DOPA-D-4+




Quinacrine Dihydrochloride ACH-M+ Lipase-A-2- OX-LP-5-
Quinacrine Dihydrochloride ACH-M+ Lipase-A-2- OX-LP-5-
Ajmalicine Hydrochloride SY-CW-
RU 24969 5HT-1-A/2-C+
Ifenprodil Tartrate ADR-A-1- EAA-G- NMDA- CHA-K(GIRK)-
Ifenprodil Tartrate ADR-A-1- EAA-G- NMDA- CHA-K(GIRK)-
ODQ CYC-GU-
Quinelorane Dihydrochloride DOPA-D-2/3+
WAY-100635 Maleate Salt 5HT-1-A- DOPA-D-4+
Buspirone 5HT-1-A+ DOPA-D-2-
PD 168077 Maleate DOPA-D-4+








Spiroxatrine 5HT-1-A- DOPA-D-2- ADR-A-2-
GR 103691 DOPA-D-3-
Droperidol DOPA-D-2-
LY 235959 EAA-G- NMDA-
Coralyne Chloride Hydrate DNA-
Trifluoperazine Hydrochloride DOPA-1-2- ADR-1- ATPase-K-
Trifluoperazine Dihydrochloride DOPA-1-2- ADR-1- ATPase-K-
YS-035 Hydrochloride CHA-CA-
















Dihydroergocristine DOPA-D-2+ ADR-A+/- 5HT-2-
Risperidone DOPA-D-2- 5HT-2- ADR-B- HIST-
Testosterone Propionate ANDR+ ESTR+
Piribedil Maleate DOPA-D-3/D-2+5HT-2-A/C-
Lisuride DOPA-D-2+ 5HT-2-B-
Carvedilol Tartrate ADR-B- ADR-1-
Risperidone DOPA-D-2- 5HT-2- ADR-B- HIST-
Phloretin CHA-CA- CHA-K-?




NAME Activity 1 Activity 2 Activity3 Activity 4
MDL 72832 5HT-1-A+ ADR-A-1?
8-Methoxy-2-Propionamidotetralin ML+









MDL 73005EF 5HT-1-A+ ADR-A-1-
p-Iodoclonidine Hydrochloride ADR-A-2+
Ethynylestradiol 3-Methylether PROG+ ESTR+
Indirubin-3-Oxime KI-CD- KI-GSK-
ARC 239 Dihydrochloride ADR-A-2-B- 5HT-1-A-
Prochlorperazine Dimaleate DOPA-D-2- ADR-A-1- HIST-H-1- 5HT-2-
Trazodone Hydrochloride 5HT-1-2- ADR-A-1- 5HT-2+(high doses)5HT-U-




Diphenhydramine Hydrochloride 5HT-U- HIST-H-1-
















Ethinyl Estradiol PROG+ ESTR+ SXR+
Chlorpheniramine  Maleate 5HT-U- ADR-U- HIST-H-1-
2-[(4-Phenylpiperazin-1Yl)Methyl]2,3-Dihydroimidazo[1,2C]Quinazolin-5(6H)-One ADR-A-1-
6-Nitroquipazine 5HT-U-
Scoulerine GABA-A+ ADR-A-1- ADR-A-1- 5HT-




Promazine Hydrochloride DOPA-1-2/4- 5HT-2-A/C- ACH-M- ADR-A-1-
NAN-190 5HT-1-A- ADR-A-1-
L(-)-Vesamicol Hydrochloride ACH-SY-
(+)-Chlorpheniramine Maleate 5HT-U- ADR-U- HIST-H-1-
Fluvoxamine Maleate 5HT-U-
Zimelidine Dihydrochloride 5HT-U-
(+/-)-SKF 82958 DOPA-D-1+ DOPA-D-2+
SKF 83565 Hydrobromide DOPA-D-1+
BMY 7378 Dihydrochloride 5HT-1-A+/- ADR-A-1-D- ADR-A-2-C-
S(-)-UH-301 Hydrochloride 5HT-1-A-







Naftifine Hydrochloride EPOX-SQ- FUNG-
(+/-)-SKF 38393, N-Allyl-, Hydrobromide DOPA-D-1+
Dydrogesterone PROG+
Brinzolamide ANC-2-
(+/-)-Brompheniramine Maleate 5HT-U- ADR-U- HIST-H-1-
Dyclonine Hydrochloride CHA-NA-
beta-Caryophyllene Alcohol
Biochanin A, Dimethyl Ether ESTR+
Picrotoxinin GABA- GLY-R-
Estradiol Cypionate ESTR+ ESTR+
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Chlorzoxazone CHA-K-(Ca)-





SIB 1757 EAA-G- mGluR5-
Enilconazole SY-CW- FUNG-
Pelletierine Hydrochloride
Imipramine Hydrochloride 5HT-U- ADR-U- ADS-A-1-
Nefopam Hydrochloride 5HT-U- DOPA-U- ADR-U- COX-


































Tranylcypromine Sulfate MAO- DOPA-D-2? 5HT-2-A?


















































































































































































































































NAME Activity 1 Activity 2 Activity3 Activity 4
SB 206553 Hydrochloride 5HT-2-B/C-
Fenoterol Hydrobromide ADR-B+
Clenbuterol Hydrochloride ADR-B-2+
Maprotiline Hydrochloride ADR-U- 5HT-U-(weak)
Maprotiline Hydrochloride ADR-U- 5HT-U-(weak)
Retinoic Acid p-Hydroxyanilide APOP+
Betamethasone ARACH- LIPCOR+ IM- GluR+






Benzyl Penicillin Potassium BACT-
Physcion BACT-
Leflunomide DH-HYO- KI-GFPL- ALOX5-
Estrone Acetate ESTR+
I-OMe-Tyrphostin AG 538 KI-IGF-1-
(-)-Eseroline Fumarate OPI-M+ ACH-(weak)
Kynurenine














Cisapride 5HT-4+ ACH+(indirect) CHA-K-
Tegaserod Maleate 5HT-4+ 5HT-2-B-
Ethylene Glycol-Bis(2-Aminoethylether)-N,N,N,N-Tetraacetic Acid ACE-2- CHEL+
Benztropine ACH-M- DOPA-U- HIST-
MG-624 ACH-N-






Chloroethylclonidine Dihydrochloride ADR-A-1- ADR-A-2+
Bretylium Tosylate ADR-B- NA/K-ATPase-
Bopindolol  Malonate ADR-B-1-
Desoxycorticosterone Acetate COR-M+ MR+
Flunisolide ARACH- LIPCOR+ IM- GluR+
Clobetasol Propionate ARACH- LIPCOR+ IM- GluR+
Hydrocortisone ARACH- LIPCOR+ IM- GluR+
6alpha-Methylprednisolone ARACH- LIPCOR+ IM- GluR+
Betamethasone Valerate ARACH- LIPCOR+ IM- GluR+
Clobetasol Propionate ARACH- LIPCOR+ IM- GluR+
Ursolic Acid ARACH- LIPCOR+ IM- GluR+
Dexamethasone ARACH- LIPCOR+ IM- GluR+
Medrysone ARACH- LIPCOR+ IM- GluR+
Betamethasone ARACH- LIPCOR+ IM- GluR+
Flumethasone ARACH- LIPCOR+ IM- GluR+




















2-Cyclooctyl-2-Hydroxyethylamine Hydrochloride NEURT- PNMT-
Theaflavin Digallate Nf-kB-?
Finasteride RED-5A-
Bufexamac SY-PG- COX- OX-C-
Diflunisal SY-PG- COX-
Fenoprofen SY-PG- COX-








Sinapic Acid Methyl Ether
IEM-1460 EAA-G- AMPA-R- NMDA-
6,7-Dichloroquinoxaline-2,3-Dione EAA-G- NMDA-
7-Chlorokynurenic Acid EAA-G- NMDA-
SDZ 220-581 EAA-G- NMDA-
L-689560 EAA-G- NMDA-




Dizocilpine Maleate EAA-G- NMDA-
(+)-MK-801 EAA-G- NMDA-
Spiperone DOPA-D-2- 5HT-1-A- 5HT-2-A-
Azobenzene
SB 228357 5HT-2-B/C-
R(-)-Isoproterenol (+)-Bitartrate ADR-B-2+ ADR-B-1+
Amitryptiline Hydrochloride ADR-U- 5HT-U- CHA-K-
Amoxapine ADR-U- 5HT-U-
Telmisartan ANG-2-1- PPAR-G+
Cefamandole Sodium SY-CW- BACT-
TCPOBOP CAR+
Cinnarazine CHA-CA- HIST-H-1- DOPA-D-2- ACH-M-
Psora-4 CHA-K-








Mianserine Hydrochloride ADR-U- ADR-A-2- HIST- 5HT-2-A/2-C-
Bepridil Hydrochloride CHA-CA- CHA-NA- CHA-K-
Aconitine CHA-NA+







Megestrol Acetate ESTR+ PROG+
1S,9R-Hydrastine GABA-A-
Chlordane GABA-A- INSECT- ATPP-Ca/Mg-ATPP-Na/K-
Dacthal HERB-
Propazine HERB-
7-Oxocallitrisic Acid, Methyl Ester
Methiothepin Maleate 5HT-1-2- DOPA-D-2-


















































































Aldrin GABA-A- INSECT- ATPP-Ca/Mg- ATPP-Na/K-
Heptachlor GABA-A- INSECT- ATPP-Ca/Mg- ATPP-Na/K-
Disulfoton ACH- INSECT-
(+)-Hydrastine GABA-A-
Dihydroergotamine Mesylate 5HT-1-D+ 5HT-1-A+ ADR-A-2-A DOPA-D-2/D-3
Amperozide Hydrochloride 5HT-2- DOPA-D-2-
Clozapine 5HT-2- DOPA-D-2- ADR- HIST-H-1-
Cephaeline Dihydrochloride Heptahydrate 5HT-4+?
Chlormadinone Acetate ANDR- ESTR+ PR+
Flutamide ANDR-
Halofantrine Hydrochloride CHA-K-
Haloperidol DOPA-D-1-2- NMDA- CHA-K-
Chlorpromazine Hydrochloride DOPA-D-2- DOPA-D-1- 5HT1-2- HIST-H-1-
3-alpha-Bis-(4-Fluorophenyl)Methoxytropane DOPA-U- ACH-M-
(-)-MK-801 Hydrogen Maleate EAA-G- NMDA-
Spermine Tetrahydrochloride EAA-G- EAA-G+ NMDA-
Epiandrosterone ESTR- CHA-CA- GABA-A+
CGP-13501 GABA-B+
2-Methoxyestradiol HIF-1-





Promethazine Hydrochloride HIST-1- ACH-M- 5HT-2- calmodulin-
Terfenadine HIST-1- CHA-K-
3-(1H-Imidazol-4-Yl)Propyl Di(P-Fluorophenyl)Methyl Ether HIST-H3-/+











MDL 72832 5HT-1-A+ ADR-A-1?
Metergoline Phenylmethyl Ester 5HT-1-D- 5HT-2- DOPA+





Imipramine Hydrochloride 5HT-U- ADR-U- ADS-A-1-
R-(-)-Fluoxetine Hydrochloride 5HT-U-
Naftopidil Dihydrochloride ADR-A-1- ADR-U-? 5HT-2-?
Naftopidil Dihydrochloride ADR-A-1- ADR-U-? 5HT-2-?
Vincamine ADR-A-1- CHA-NA-
Oxymetazoline Hydrochloride ADR-A-1+ ADR-A-2+
Yohimbine Hydrochloride ADR-A-2-
Beclomethasone Dipropionate ARACH- LIPCOR+ IM- GluR+
Rutilantinone BACT-
Verapamil Hydrochloride CHA-CA-
Acetopromazine Maleate Salt DOPA-
Azaperone DOPA- HIST- ACH-
Triflupromazine Hydrochloride DOPA-D-1/D-1- 5HT-2-B- ACH-M-
Haloperidol DOPA-D-1-2- NMDA- CHA-K-
L-741626 DOPA-D-2-
Thioridazine Hydrochloride DOPA-D-2- 5HT-2- ADR- CHA-K-
Mesulergine Hydrochloride DOPA-D-2+ 5HT-2-C-
CNS-1102 EAA-G- NMDA-





Meclozine Dihydrochloride HIST- ACH-












Metergoline 5HT-1-D- 5HT-2- DOPA+
Dihydroergotamine Methanesulfonate 5HT-1-D+ 5HT-1-A+ ADR-A-2-A DOPA-D-2/D-3
Ketanserin Tartrate 5HT-2- DOPA?
Pirenperone 5HT-2- DOPA-D-2-?
Ketanserin Tartrate 5HT-2- DOPA?
Paroxetine Hydrochloride Hemihydrate 5HT-U-
Trihexyphenidyl Hydrochloride ACH-M-1-




Ifenprodil Tartrate ADR-A-1- EAA-G- NMDA- CHA-K(GIRK)-
Nicergoline ADR-A-1-
3,4-Dimethoxyflavone AHR-
Androsterone Acetate ANDR+ CHA-CA-?
Totarol BACT-
Phenamil CHA-NA-
Azaperone DOPA- HIST- ACH-
Spiperone Hydrochloride DOPA-D-2- 5HT-1-A- 5HT-2-A-
Benperidol DOPA-D-2- CHA-K-
Spiperone DOPA-D-2- 5HT-1-A- 5HT-2-A-
Droperidol DOPA-D-2- CHA-K-
DO 897/99 DOPA-D-2/D-3- DOPA-D-3+ 5-HA-1-A ADR-A-1
Risperidone DOPA-D-2- 5HT-2- ADR-B- HIST-
S(-)-Lisuride DOPA-D-2+ 5HT-2-B-
Dihydroergocristine DOPA-D-2+ ADR-A+/- 5HT-2-
Dihydroergocristine DOPA-D-2+ ADR-A+/- 5HT-2-
Bromocriptine Mesylate DOPA-D-2+ CREB+ SSTATIN
PD 168077 DOPA-D-4+
Ro 25-6981 Hydrochloride EAA-G- NMDA-NR2-B-
Butylparaben ESTR?
Hydroxyprogesterone Caproate ESTR+ ESTR+ PR+
Alfadolone Acetate GABA-A+
Reserpine NEURT-
Saquinavir Mesylate PROT- TNF-alpha+ PROL-
Nomegestrol Acetate PROG+ ANDR-
Ethynodiol Diacetate PROG+ ESTR+
Oxaprozin SY-PG- COX-






Strophanthidinic Acid Lactone Acetate ATPP-Na/K-
Vinpocetine CHA-NA- ES-P-C-1-
Medroxyprogesterone Acetate DEC-OR- ANDR- ESTR+ PR+
Domperidone DOPA-D-2-
3-Methoxymorphinan Hydrochloride EAA-G- NMDA- OPI-S+ DOPA-U-?
L-701252 EAA-G- NMDA-
4-Androstene-3,17-Dione ESTR- ANDR+









































































Spiroxatrine 5HT-1-A- DOPA-D-2- ADR-A-2-
WAY-100635 Maleate Salt 5HT-1-A- DOPA-D-4+
RU-24969 5HT-1-A/2-C+
CINANSERIN 5HT-2-
Opipramol Dihydrochloride 5HT-2- OPI-S+ HIST-H-1- DOPA-D-2-
Norcyclobenzaprine 5HT-2-A-
Alcuronium Chloride ACH-M-
Quinacrine Dihydrochloride ACH-M+ Lipase-A-2- OX-LP-5-





Ifenprodil Tartrate ADR-A-1- EAA-G- NMDA- CHA-K(GIRK)-






RX 821002 Hydrochloride ADR-A-2-
Testosterone Propionate ANDR+ ESTR+




Mexiletine Hydrochloride CHA-NA- ADR-B-
ODQ CYC-GU-




Risperidone DOPA-D-2- 5HT-2- ADR-B- HIST-











Trazodone Hydrochloride 5HT-1-2- ADR-A-1- 5HT-2+(high doses)5HT-U-
P-MPPF Dihydrochloride 5HT-1-A-
WAY-100635 Maleate 5HT-1-A- DOPA-D-4+
MDL-73005EF 5HT-1-A+ ADR-A-1-
BMY 7378 Dihydrochloride 5HT-1-A+/- ADR-A-1-D- ADR-A-2-C-
GR 127935 Hydrochloride 5HT-1-B/D- 5HT-1-D+?
Clozapine 5HT-2- DOPA-D-2- ADR- HIST-H-1-
N-Methylquipazine 5HT-3+
(+)-Chlorpheniramine Maleate 5HT-U- ADR-U- HIST-H-1-
Diphenhydramine Hydrochloride 5HT-U- HIST-H-1-
Fluvoxamine Maleate 5HT-U-
Imipramine Hydrochloride 5HT-U- ADR-U- ADS-A-1-
Paroxetine Hydrochloride 5HT-U-






ARC 239 Dihydrochloride ADR-A-2-B- 5HT-1-A-
Carvedilol Tartrate ADR-B- ADR-1-







Apomorphine Hydrochloride DOPA+ COMT- TH-
Trifluoperazine Dihydrochloride DOPA-1-2- ADR-1- ATPase-K-
Trifluoperazine Hydrochloride DOPA-1-2- ADR-1- ATPase-K-
Piperacetazine DOPA-D-1/D-2-? 5HT-2-B-?




Prochlorperazine Dimaleate DOPA-D-2- ADR-A-1- HIST-H-1- 5HT-2-
Risperidone DOPA-D-2- 5HT-2- ADR-B- HIST-
Quinelorane Dihydrochloride DOPA-D-2/3+
S(-)-Lisuride DOPA-D-2+ 5HT-2-B-
B-HT 920 DOPA-D-2+ ADR-A-2+ 5HT-3-
Dipropyl-6,7-ADTN DOPA-D-2+




Harmane Hydrochloride GABA-A 5HT-2-A+ CHA-









GW 9662 PPAR-G- IL-4-











BMY 7378 Dihydrochloride 5HT-1-A+/- ADR-A-1-D- ADR-A-2-C-
Quipazine 5HT-2-A/3+
Quipazine Dimaleate 5HT-2-A/3+
Dl-p-Chlorophenylalanine Methyl Ester Hydrochloride 5HT-SY-
6-Nitroquipazine 5HT-U-









Promazine Hydrochloride DOPA-1-2/4- 5HT-2-A/C- ACH-M- ADR-A-1-
(+/-)-Chloro-APB Hydrobromide DOPA-D-1+
(+/-)-SKF 82958 DOPA-D-1+ DOPA-D-2+
R(+)-6-Bromo-APB Hydrobromide DOPA-D-1+
SKF 83565 Hydrobromide DOPA-D-1+
Prochlorperazine Dimaleate DOPA-D-2- ADR-A-1- HIST-H-1- 5HT-2-
S-(-)-Eticlopride Hydrochloride DOPA-D-2/D-3-
L-750667 DOPA-D-4-
PD 168077 Maleate DOPA-D-4+
1-[1-(2-Benzo[B]Thienyl)Cyclohexyl]Pyrrolidine DOPA-U-
Dextromethorphan Hydrobromide Monohydrate EAA-G- NMDA- OPI-S+ DOPA-U-?
SIB 1757 EAA-G- mGluR5-
Syrosingopine NEURT-
6(5H)-Phenanthridinone PARP-
Ethinyl Estradiol PROG+ ESTR+ SXR+
Benfluorex Hydrochloride RED-HMG-?
Suprofen Methyl Ester SY-PG- COX-1- COX-2-












































































NAN-190 Hydrobromide 5HT-1-A- ADR-A-1-
N-Butyl-N-Ethyl-2-(1-Naphthyloxy)Ethanamine 5HT-1-A+
CGS-12066A Maleate 5HT-1-B+ 5HT-1-D+
Quipazine Maleate 5HT-2-A/3+
Tropanyl 3,5-Dimethylbenzoate 5HT-3-
(+/-)-Brompheniramine Maleate 5HT-U- ADR-U- HIST-H-1-
Amitriptyline Hydrochloride 5HT-U- ADR-U-
Fluoxetine Hydrochloride 5HT-U-
Imipramine Hydrochloride 5HT-U- ADR-U- ADS-A-1-


































Bromocriptine Mesylate DOPA-D-2+ CREB+ SSTATIN
S(-)-DS 121 Hydrochloride DOPA-D-3-
Ropinirole Hydrochloride DOPA-D-3/2+
SIB 1757 EAA-G- mGluR5-
Naftifine Hydrochloride EPOX-SQ- FUNG-
(-)-Huperzine A ES-ACH-
Biochanin A, Dimethyl Ether ESTR+










Tranylcypromine Hydrochloride MAO- DOPA-D-2? 5HT-2-A?















1,3-Diethyl-8-Phenylxanthine ADS-A-1- ES-P-C-IV- Nf-kB
Ciclopirox Olamine PERM- ATPP-Na/K-
DCEBIO CHA-K+





























Indomethacin Morpholinylamide SY-PG- COX-1-2-
Thioxolone ANC-2-
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Average Waking Activity ,1552,*(D)Zimelidine Dihydrochloride


















































Average Waking Activity ,666,Fluvoxamine Maleate


















































Average Waking Activity ,491,(+)-Chlorpheniramine Maleate


















































Average Waking Activity ,3584,6-Nitroquipazine



































































































Waking Activity                 Rest



























Average Waking Activity ,4797,Heptachlor



























Average Waking Activity ,4804,Aldrin



























Average Waking Activity ,4915,*(H)Chlordane














































































































Average Waking Activity ,4907,*(D)Toxaphene






















































































































































































A.                                    B.
C.                                                      D.
NAN-190 5-HT1A antagonist













PD 168077 dopamine agonist
Dihydroergocristine alpha-1 antagonist
















16    Vincamine 0.817
17 H-89 0.813
18 WAY-100635 0.813









































































































































































































































































































































































































Waking Activity                   Rest
Figure S8





















Average Waking Activity ,915,Ifenprodil Tartrate
















































Average Waking Activity ,3739,Clonidine















































Average Waking Activity ,5356,Clenbuterol Hydrochloride











































































































Ifenprodil mixed effects (S30-33)




Bopindolol reduced activity, (S34, S35)
Carvedilol sedation
28















































Average Waking Activity ,666,Fluvoxamine Maleate
















































Average Waking Activity ,1248,Ketanserin Tartrate















































Average Waking Activity ,2503,Metergoline Phenylmethyl Ester





















Average Waking Activity ,3727,Nan-190
















































Average Waking Activity ,3616,Quipazine





















Average Waking Activity ,692,Dihydroergotamine Methanesulfonate























































































































































































































































































































GR 46611 potentiates 5HT-1A induced 
































(S53-55)improves insomnia in 
patients; REM suppression; 
biphasic effects on SWS in 
rats/cats -- up short term, 
down long term
increased sleep; increased 
exploration
reduced locomotion;      
initial sleep suppression 
followed by long term SWS 
increase
short term increases in 
waking; long term increases 
in SWS (humans, rats, cats)
short term increases in 
waking followed by general 
deactivation
short-term sleep 
suppression; long term 
increase in SWS 
29
















































Average Waking Activity ,885,S(-)-Ds 121 Hydrochloride















































Average Waking Activity ,2913,Benperidol























Average Waking Activity ,1274,R(-)-Sch-12679 Maleate























Average Waking Activity ,3574,Pd 168077








































































Average Waking Activity ,2347,R(-)Apomorphine Hydrochloride Hemihydrate


















































































































































































































Average Waking Activity ,1399,Ropinirole Hydrochloride


























































































short term increase in 
waking followed by long-
term increases in sleep 
amount
increased waking, reduction 
in sleep (rat and monkeys), 
and increased grooming
biphasic; at low 
concentrations, reduces 
waking and locomotor 
activity, and increases 
sleep.  At high doses, the 
opposite.
reduced waking; no 


























































Average Waking Activity ,3397,Alfadolone Acetate










































































Average Waking Activity ,410,Cgp-13501





















Average Waking Activity ,3474,*(D)Tracazolate Hydrochloride























Average Waking Activity ,4354,"*(S)1S,9R-Hydrastine"




















































































































































































































increased locomtor activity; 
induction of fighting;                                                    
pro-convulsant
anxiolytic; dose dependant 
increase or decrease in 
locomotor activity




























Average Waking Activity ,919,Iik7























Average Waking Activity ,1952,8-Methoxy-2-Propionamidotetralin

































































































































































































increase in sleep propensity 
in dirunal species; circadian 
phase shifting
blocks melatonin effects on 
behavior
32























Average Waking Activity ,2615,Clemizole hydrochloride

















































Average Waking Activity ,5553,Clemastine

















































Average Waking Activity ,5651,Diphenylpyraline Hydrochloride




























































































































sedation (less pronounced 
in loratadine)
some sedation in 1st 
generation anti-histamines; 
less pronounced in second 
generation anti-histamines
33

















































Average Waking Activity ,2210,Mrs 1220























Average Waking Activity ,599,"8-Cyclopentyl-1,3-Dipropylxanthine"










































































































































































































































































































































Average Waking Activity ,1990,2-Methyl-6-(phenylethynyl)pyridine
Figure S15
Time Time
























































































































































0uM 100nM 300nM 1uM 3uM 10uM 30uM
Day
Night
B.  YS-03  Rest C.  YS-035 Waking Activity
A.
Time Time



























































Average Waking Activity ,83,Methoxy Verapamil
YS-035
Methoxy- erapamil



























Average Waking Activity ,1546,Ys-035 Hydrochloride














































































































































Average Waking Activity ,2351,Verapam l Hydrochloride




























































Average Waking Activity ,2351,Verapamyl Hydrochloride









































































Average Waking Activity ,2351,Verapamyl Hydrochloride






























































Average Waking Activity ,2351,Verapamyl Hydrochloride




































































































Average Waking Activity ,318,Betamethasone

























Average Waking Activity ,2764,Cyclosporin A

























Average Waking Activity ,4662,Fosfosal
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Effective Dose Correlated Dose Range
Clonidine 45 µM 1.5 µM 1.5-45 µM
Ropinirole 45 µM 0.45 µM 0.45-45 µM
NAN-190 30 µM 0.10 µM 0.10-30 µM
MK-801 45 µM 0.45 µM 0.45-45 µM
Betamethasone 45 µM 0.15 µM 0.15-45 µM
Chloro-APB 45 µM 0.45 µM 0.45-45 µM
Buspirone 45 µM 4.5 µM 4.5-45 µM
Cyclosporin A 45 µM 2 µM 2-45 µM
Ketanserin 15 µM 0.15 µM 0.15-45 µM
Nicergoline 15 µM 1.5 µM 4.5-45 µM
Quipazine 45 µM 1.5 µM 0.15-45 µM
Warfarin 45 µM 4.5 µM 4.5-45 µM
Fluvoxamine 45 µM 1.5 µM 0.45-45 µM
Valproic Acid 45 µM 15 µM 0.45-45 µM
Carvedilol 4.5 µM 0.45 µM 0.45-4.5 µM
2-Chloroadenosine 45 µM 45 µM 0.15-45 µM
Phenelzine 45 µM 45 µM 4.5-15 µM
Trazodone 45 µM 1.5 µM 1.5-15 µM
Clozapine 15 µM 1.5 µM 1.5-15 µM
Amoxapine 30 µM 3.0 µM 1.0-10 µM
Cyclobenzaprine 15 µM 4.5 µM 1.5-15 µM
Fluoxetine 15 µM 1.5 µM 1.5-4.5 µM
Haloperidol 15 µM 1.5 µM 0.15-1.5 µM
Loxapine 15 µM 0.45 µM 0.15-4.5 µM
Papaverine 3.0 µM 1.0 µM 0.30-3.0 µM
Pergolide 45 µM 0.45 µM 4.5-45 µM; 0.15-1.5 µM
Bromocriptine 15 µM 0.15 µM 1.5-15 µM; 0.15-1.5 µM
Dihydroergotamine 45 µM 0.15 µM 4.5-45 µM; 0.15-1.5 µM
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